{"id":23068,"date":"2025-12-26T10:26:41","date_gmt":"2025-12-26T15:26:41","guid":{"rendered":"https:\/\/www.ices.on.ca\/?post_type=journal_article&#038;p=23068"},"modified":"2026-01-07T10:34:56","modified_gmt":"2026-01-07T15:34:56","slug":"impact-of-age-and-frailty-on-acute-care-use-during-immune-checkpoint-inhibitor-treatment","status":"publish","type":"journal_article","link":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/impact-of-age-and-frailty-on-acute-care-use-during-immune-checkpoint-inhibitor-treatment\/","title":{"rendered":"Impact of age and frailty on acute care use during immune checkpoint inhibitor treatment"},"content":{"rendered":"<p><strong>Purpose<\/strong> \u2014 Older and frail adults were under-represented in clinical trials evaluating ICIs, leading to a knowledge gap on their risk of acute care use and immune-related adverse events (irAEs). We performed a population-level study evaluating the impact of age and frailty among older adults receiving ICIs on acute care use and irAE-related hospitalizations.<\/p>\n<p><strong>Methods<\/strong> \u2014 Patients with cancer, age\u2009\u2265\u200965 initiating ICIs between June 2012-October 2018 (Ontario, Canada) were identified using systemic therapy administration data. The cohort was linked to other databases to obtain covariates and outcomes. Multivariable Cox proportional models evaluated the impact of age and frailty on acute care use and irAE-related hospitalizations.<\/p>\n<p><strong>Results<\/strong> \u2014 Among 2,737 patients, median age was 73 and 26% were pre-frail and 4% frail; 72% required acute care use, while 8% had an irAE-related hospitalization. Increasing frailty was associated with increased risk of acute care use (pre-frail vs robust, aHR\u2009=\u20091.20,95% CI[1.07-1.36], p\u2009=\u2009.003; frail vs robust, aHR\u2009=\u20091.45[1.12-1.86], p\u2009=\u2009.004), while age was not associated with acute care use. Increasing age was associated with reduced risk of irAE-related hospitalization (aHR\u2009=\u20090.97 per year[0.95-0.99], p\u2009=\u2009.01); patients age\u2009\u2265\u200980 compared to 65-69 had reduced risk of irAE-related hospitalization (aHR\u2009=\u20090.63[0.39-1.01], p\u2009=\u2009.05). Frailty was not associated with irAE-related hospitalizations. Associations remained consistent when evaluating age and frailty in the same models.<\/p>\n<p><strong>Conclusions<\/strong> \u2014 Age was associated with reduced risk of an irAE-related hospitalization but not acute care use, while increasing frailty was associated acute care use, but not irAE-related hospitalization. Age and frailty may need to be considered independently when evaluating their impact on toxicity among older adults receiving ICIs.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Purpose \u2014 Older and frail adults were under-represented in clinical trials evaluating ICIs, leading to a knowledge gap on their risk of acute care use and immune-related adverse events (irAEs). We performed a population-level study evaluating the impact of age and frailty among older adults receiving ICIs on acute care use and irAE-related hospitalizations. Methods [&hellip;]<\/p>\n","protected":false},"template":"","migration-helper-automated":[],"migration-manual":[],"topic":[24,62,17,56],"migration-helper-qa-sample-set":[],"class_list":["post-23068","journal_article","type-journal_article","status-publish","hentry","topic-acute-and-emergency-services","topic-health-services-research","topic-older-people","topic-pharmacoepidemiology-and-drug-safety"],"acf":{"citation":"Eng L, Faour E, Sutradhar R, Kaliwal Y, Niu Y, Liu N, Liu Y, Powis M, Liu G, Peppercorn JM, Krzyzanowska MK, Alibhai SMH. <em>J Natl Cancer Inst<\/em>. 2025; Dec 26 [Epub ahead of print].","source_url":"https:\/\/doi.org\/10.1093\/jnci\/djaf373","ices_scientist":[1370,20183,1151],"site":[6733],"research_program":[6741],"news_release":"","journal_article":"","atlas":"","research_report":"","infographic":"","video":"","downloads":null,"links":null,"sitecore_item_id":"","sitecore_item_name":"","sitecore_field_values":"","previous_url":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ICES | Impact of age and frailty on acute care use during immune checkpoint inhibitor treatment<\/title>\n<meta name=\"description\" content=\"Purpose \u2014 Older and frail adults were under-represented in clinical trials evaluating ICIs, leading to a knowledge gap on their risk of acute care use and\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/impact-of-age-and-frailty-on-acute-care-use-during-immune-checkpoint-inhibitor-treatment\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ICES | Impact of age and frailty on acute care use during immune checkpoint inhibitor treatment\" \/>\n<meta property=\"og:description\" content=\"Purpose \u2014 Older and frail adults were under-represented in clinical trials evaluating ICIs, leading to a knowledge gap on their risk of acute care use and\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/impact-of-age-and-frailty-on-acute-care-use-during-immune-checkpoint-inhibitor-treatment\/\" \/>\n<meta property=\"og:site_name\" content=\"ICES\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ICESOntario\/\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-07T15:34:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/impact-of-age-and-frailty-on-acute-care-use-during-immune-checkpoint-inhibitor-treatment\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/impact-of-age-and-frailty-on-acute-care-use-during-immune-checkpoint-inhibitor-treatment\\\/\",\"name\":\"ICES | Impact of age and frailty on acute care use during immune checkpoint inhibitor treatment\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\"},\"datePublished\":\"2025-12-26T15:26:41+00:00\",\"dateModified\":\"2026-01-07T15:34:56+00:00\",\"description\":\"Purpose \u2014 Older and frail adults were under-represented in clinical trials evaluating ICIs, leading to a knowledge gap on their risk of acute care use and\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/impact-of-age-and-frailty-on-acute-care-use-during-immune-checkpoint-inhibitor-treatment\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/impact-of-age-and-frailty-on-acute-care-use-during-immune-checkpoint-inhibitor-treatment\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/impact-of-age-and-frailty-on-acute-care-use-during-immune-checkpoint-inhibitor-treatment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Journal Articles\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Impact of age and frailty on acute care use during immune checkpoint inhibitor treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"name\":\"ICES\",\"description\":\"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\"},\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\",\"name\":\"ICES\",\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"contentUrl\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"width\":\"676\",\"height\":\"618\",\"caption\":\"ICES\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ICESOntario\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ices-research-institute\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ICES | Impact of age and frailty on acute care use during immune checkpoint inhibitor treatment","description":"Purpose \u2014 Older and frail adults were under-represented in clinical trials evaluating ICIs, leading to a knowledge gap on their risk of acute care use and","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/impact-of-age-and-frailty-on-acute-care-use-during-immune-checkpoint-inhibitor-treatment\/","og_locale":"fr_FR","og_type":"article","og_title":"ICES | Impact of age and frailty on acute care use during immune checkpoint inhibitor treatment","og_description":"Purpose \u2014 Older and frail adults were under-represented in clinical trials evaluating ICIs, leading to a knowledge gap on their risk of acute care use and","og_url":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/impact-of-age-and-frailty-on-acute-care-use-during-immune-checkpoint-inhibitor-treatment\/","og_site_name":"ICES","article_publisher":"https:\/\/www.facebook.com\/ICESOntario\/","article_modified_time":"2026-01-07T15:34:56+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/impact-of-age-and-frailty-on-acute-care-use-during-immune-checkpoint-inhibitor-treatment\/","url":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/impact-of-age-and-frailty-on-acute-care-use-during-immune-checkpoint-inhibitor-treatment\/","name":"ICES | Impact of age and frailty on acute care use during immune checkpoint inhibitor treatment","isPartOf":{"@id":"https:\/\/www.ices.on.ca\/fr\/#website"},"datePublished":"2025-12-26T15:26:41+00:00","dateModified":"2026-01-07T15:34:56+00:00","description":"Purpose \u2014 Older and frail adults were under-represented in clinical trials evaluating ICIs, leading to a knowledge gap on their risk of acute care use and","breadcrumb":{"@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/impact-of-age-and-frailty-on-acute-care-use-during-immune-checkpoint-inhibitor-treatment\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/impact-of-age-and-frailty-on-acute-care-use-during-immune-checkpoint-inhibitor-treatment\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/impact-of-age-and-frailty-on-acute-care-use-during-immune-checkpoint-inhibitor-treatment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ices.on.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Journal Articles","item":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/"},{"@type":"ListItem","position":3,"name":"Impact of age and frailty on acute care use during immune checkpoint inhibitor treatment"}]},{"@type":"WebSite","@id":"https:\/\/www.ices.on.ca\/fr\/#website","url":"https:\/\/www.ices.on.ca\/fr\/","name":"ICES","description":"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE","publisher":{"@id":"https:\/\/www.ices.on.ca\/fr\/#organization"},"alternateName":"Institute for Clinical Evaluative Sciences","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ices.on.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ices.on.ca\/fr\/#organization","name":"ICES","alternateName":"Institute for Clinical Evaluative Sciences","url":"https:\/\/www.ices.on.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","contentUrl":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","width":"676","height":"618","caption":"ICES"},"image":{"@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ICESOntario\/","https:\/\/www.linkedin.com\/company\/ices-research-institute\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article\/23068","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article"}],"about":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/types\/journal_article"}],"acf:post":[{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/research_program\/6741"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/site\/6733"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1151"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/20183"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1370"}],"wp:attachment":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/media?parent=23068"}],"wp:term":[{"taxonomy":"migration-helper-automated","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-automated?post=23068"},{"taxonomy":"migration-manual","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-manual?post=23068"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/topic?post=23068"},{"taxonomy":"migration-helper-qa-sample-set","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-qa-sample-set?post=23068"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}